Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study.
about
Effects of beta-blockers on heart failure with preserved ejection fraction: a meta-analysisAssessing the impact of heart failure specialist services on patient populationsThirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction: A Network Meta-AnalysisSurgical ventricular restoration to reverse left ventricular remodeling.Current and emerging antiarrhythmic drug therapy for ventricular tachycardiaPatterns of beta-blocker intensification in ambulatory heart failure patients and short-term association with hospitalization.Severe iatrogenic bradycardia related to the combined use of beta-blocking agents and sodium channel blockersPeri-operative beta-blockade and haemodynamic optimisation in patients with coronary artery disease and decreasing exercise capacity presenting for major noncardiac surgery.The implications of physical activity in patients with chronic heart failure.Cardiac Effects of Attenuating Gsα - Dependent SignalingCritical differences among beta-adrenoreceptor antagonists in myocardial failure: debating the MERIT of COMET.Effectiveness of beta-blocker therapy in daily practice patients with advanced chronic heart failure; is there an effect-modification by age?Hypertension and heart failure: role of neurohormonal mechanisms.Early initiation of beta blockade in heart failure: issues and evidence.The current prevalence of sleep disordered breathing in congestive heart failure patients treated with beta-blockers.The role of adrenergic receptor polymorphisms in heart failure.Profile of carvedilol controlled-release: a new once-daily formulation of carvedilol.Beta-blocker therapy of heart failure: an update.Modulation of beta-adrenergic receptor signaling in heart failure and longevity: targeting adenylyl cyclase type 5.Carvedilol in the treatment of elderly patients with chronic heart failure.Carvedilol increases blood pressure response to phenylephrine infusion in heart failure subjects with systolic dysfunction: evidence of improved vascular alpha1-adrenoreceptor signal transduction.Do general practitioners follow treatment recommendations from guidelines in their decisions on heart failure management? A cross-sectional studySystematic review of genuine versus spurious side-effects of beta-blockers in heart failure using placebo control: recommendations for patient information.Triage after hospitalization with advanced heart failure: the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness) risk model and discharge score.Prognosis and natural history of drug-related bradycardia.Role of carvedilol controlled-release in cardiovascular disease.Digoxin reduces 30-day all-cause hospital admission in older patients with chronic systolic heart failure.Efficacy of Intravenous Administration of Landiolol in Patients With Acute Heart Failure and Supraventricular Tachyarrhythmia.β-blockers and their mortality benefits: underprescribed in heart failure and chronic obstructive pulmonary disease.Myocardial regeneration in heart failure: integrated development of biological therapeutic approaches.Non-withdrawal of beta blockers in acute decompensated chronic and de novo heart failure with reduced ejection fraction in a prospective multicentre study of patients with acute heart failure in the Middle East.The patient with left ventricular systolic dysfunction now and in the future.Carvedilol in chronic heart failure: past, present and future.Resynchronization therapy is an important advance in the management of congestive heart failure: view of an antagonist.[Heart failure update 2010 and current ESC guidelines].Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN).Tolerability of beta-blocker initiation and titration with bisoprolol and carvedilol in congestive heart failure -- a randomized comparison.Impact of beta-2 Thr164Ile and combined beta-adrenergic receptor polymorphisms on prognosis in a cohort of heart failure outpatients.An appropriate indication for the initiation of beta-blocker therapy in dilated cardiomyopathy.Carvedilol case history: the discovery and development of the first β-blocker for the treatment of congestive heart failure.
P2860
Q21132299-2A127078-4BB1-4918-A5AA-E72F8AF5AB73Q24796348-800434FE-8CAF-4E09-A630-E945B5035110Q30239022-D6F507AF-B611-4EBD-8BC0-47BF5BDEEFD7Q33754169-EFF1D1AE-07BB-4DF2-A62F-590A5D68BB2AQ33936131-D6E9B332-B7F4-4F27-9D41-ABA3326DBFADQ34307931-F3EC2E3D-8B13-42D0-AF96-4B4C48D2E7B9Q35110915-35F37C6F-40F5-46E1-A675-7FC5A8127C4FQ35612101-AD4F783A-B8E5-48C4-B3ED-E3843A871264Q35660774-9B06F898-32D9-48A3-84AE-D88D757D8CDCQ35904773-E08BD668-0453-4D5B-8855-0DD3FC3F961CQ35985739-5BAD5F5B-0018-4510-B1A5-D886B805BBC8Q36025044-BE7AD35D-53D0-47E4-9561-B04AEF505484Q36035785-5ACF38D5-856E-4939-80C8-7987F6FDAAC3Q36287752-AAF02AB4-14D2-4DEE-9293-1958293D648DQ36513398-FE3DAD24-671B-4AA8-9B1A-3803952B546BQ36629879-AD68259B-E98B-4308-A0F9-498B843CC1E2Q36675404-8552853C-372A-431F-B699-689CEFFCE369Q36723828-311E1213-353A-4A92-91DB-C584AECC4FD4Q36848480-16A8B86A-B838-4F3E-874D-9FB15717A960Q36892905-A0E7153B-7E2C-4694-9C89-167760F94CE3Q36961345-A58A45D1-402F-49DA-B4D0-DEE649C3E852Q37190371-AA786DAE-2CA7-406B-B8FC-FFF1B0CB06B1Q37285522-3BAA0C2B-7D22-426B-B43A-FA605325F6A8Q37328512-D6C72287-DE68-44D2-B9C1-CBF9466DF05BQ37408756-2AE07820-27B2-4D5C-A9DC-8B211267ADADQ37472042-98A5C388-90DE-42A9-A811-C1596D38D15EQ37588012-647D2E2D-6F8E-481F-8B2C-12987D9C53BAQ37737193-0F7A3F42-B41D-4DEB-8511-97A33179D90EQ37822723-93E8AE16-B36E-4C88-B06B-6D32DC694289Q37923971-C98E021B-A309-4840-B873-66D97053D129Q38685401-63CD004D-2C4C-4772-9B62-3ED5AEFA801EQ38820073-637CE4B5-10F8-4FD7-AA54-FDA9B87EEEA6Q40377169-9A17EBBA-0558-441E-9713-1F3087D7DD4EQ40564909-B7A6069A-4F40-4F89-8AE2-0B2C5340D728Q42835997-90357123-0661-48A5-A184-79CB3E6EBE90Q44925682-63961A0D-16D9-4268-940E-AA73CB93EFB4Q45034589-E0A35A4E-FF7B-4AEF-A237-B3FCDEE90600Q46046251-04D219E0-29E4-416A-9866-AABCFBFA4D53Q46792937-5AB49737-ECDC-48AA-A24C-5301DD705C85Q47595649-46D4DB1D-C4DE-41A3-A2BF-4493F091681B
P2860
Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Effects of initiating carvedil ...... lts from the COPERNICUS Study.
@en
Effects of initiating carvedil ...... lts from the COPERNICUS Study.
@nl
type
label
Effects of initiating carvedil ...... lts from the COPERNICUS Study.
@en
Effects of initiating carvedil ...... lts from the COPERNICUS Study.
@nl
prefLabel
Effects of initiating carvedil ...... lts from the COPERNICUS Study.
@en
Effects of initiating carvedil ...... lts from the COPERNICUS Study.
@nl
P2093
P356
P1476
Effects of initiating carvedil ...... lts from the COPERNICUS Study.
@en
P2093
Andrew J S Coats
Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group
Ellen B Roecker
Hugo A Katus
Jean L Rouleau
Michael B Fowler
Milton Packer
Paul Mohacsi
P304
P356
10.1001/JAMA.289.6.712
P407
P577
2003-02-01T00:00:00Z